Maurice Anidjar
Overview
Explore the profile of Maurice Anidjar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hesswani C, Avolio P, Rompre-Brodeur A, Ghai S, Anidjar M, Kinnaird A, et al.
J Endourol
. 2024 Nov;
PMID: 39612186
This article equips Canadian urologists with the latest advancements in focal therapy (FT) principles and outcomes while providing an overview of its current landscape in Canada, including challenges and future...
2.
Avolio P, Hassan T, Addar A, Alshamsi H, McPherson V, Buffi N, et al.
J Endourol
. 2024 Nov;
PMID: 39587895
Multiparametric magnetic resonance imaging (mpMRI) has made dramatic inroads into the management of localized prostate cancer (PCa); however, not all suspicious lesions represent clinically significant (cs) PCa. We aimed to...
3.
Kumar R, Ghai S, Finelli A, Klotz L, Kinnaird A, Mannas M, et al.
Can Urol Assoc J
. 2024 Oct;
19(2):63-72.
PMID: 39418491
Introduction: Focal therapy is an emerging treatment for localized prostate cancer (PCa). The objectives of this review were to: 1) review how focal therapies are regulated and approved; 2) summarize...
4.
Avolio P, Hassan T, Addar A, Alshamsi H, McPherson V, Loutochin O, et al.
Can Urol Assoc J
. 2024 Jul;
18(11):E312-E318.
PMID: 38976899
Introduction: We aimed to compare the detection rate of prostate cancer (PCa) and clinically significant (cs) PCa by magnetic resonance imaging-guided targeted biopsy (MTBx) alone and MTBx plus systematic biopsy...
5.
Fugaru I, Bouhadana D, Marcq G, Moryousef J, Rompre-Brodeur A, Meng A, et al.
Can J Urol
. 2024 Feb;
31(1):11784-11792.
PMID: 38401258
Introduction: Partial gland ablation (PGA) using high intensity focal ultrasound (HIFU) is an alternative to active surveillance for low to intermediate risk localized prostate cancer. This pilot study assessed quality...
6.
Klotz L, Chin J, Black P, Finelli A, Anidjar M, Machado A, et al.
Eur Urol Oncol
. 2023 Oct;
7(3):456-461.
PMID: 37838556
Background: The prospective randomized PRECISE trial demonstrated that magnetic resonance imaging (MRI) with only targeted biopsy (TBx) was noninferior to systematic transrectal ultrasound biopsy (SBx) in the detection of International...
7.
Avolio P, Lughezzani G, Anidjar M, Hassan T, Rompre-Brodeur A, Buffi N, et al.
World J Urol
. 2023 Aug;
41(11):3267-3276.
PMID: 37555985
Purpose: Micro-UltraSound (microUS) is a new imaging modality capable of identifying and targeting suspicious areas, which might further increase the diagnostic yield of prostate biopsy (PBx). Aim of this review...
8.
Niazi T, Kaldany E, Tisseverasinghe S, Malagon T, Bahoric B, McPherson V, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444553
Purpose: The present phase III randomized trial assessed the efficacy of prophylactic versus therapeutic α-blockers at improving RI-LUTSs in prostate cancer patients receiving external beam radiotherapy (EBRT). Methods: A total...
9.
Cartes R, Karim M, Tisseverasinghe S, Tolba M, Bahoric B, Anidjar M, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444473
Background: There is an ongoing debate on the optimal sequencing of androgen deprivation therapy (ADT) and radiotherapy (RT) in patients with localized prostate cancer (PCa). Recent data favors concurrent ADT...
10.
Tisseverasinghe S, Bahoric B, Anidjar M, Probst S, Niazi T
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980735
Poly-adenosine diphosphate-ribose polymerase plays an essential role in cell function by regulating apoptosis, genomic stability and DNA repair. PARPi is a promising drug class that has gained significant traction in...